The Proton Therapy Center (PTC) Czech assembled data on 86 prostate cancer patients treated at the center between December 2012 and December 2014, all with non-metastatic prostate cancer without previous surgical intervention. There were no cases of biochemical relapse and very good toxicity levels, generally staying below the Intensity Modulated Radiation Therapy (IMRT) values found in literature, with 5-10% better survival rates and two- to three-fold lower incidence of late adverse events.

The patients were either treated with proton radiotherapy in the stereotactic (hypo-fractionation) mode alone or in combination with hormonal therapy. Proton therapy was given in doses of 36.25 CGE per fraction at a total of 5 fractions, leading to a median total treatment duration of nine days. Neoadjuvant hormonal therapy was given to 16 patients. At a median follow-up of 11 months, there were no Prostate-Specific Antigen (PSA) relapses observed. Acute gastroenterologic and urologic (GU) grade 2 toxicities were observed in 15.1% of the patients, and grade 1 toxicities were observed in 56.9% of patients. Acute gastro-intestinal (GI) grade 3 toxicities were limited to 3.4% of the patients while 81.3% showed grade 1 GI toxicities. No patients developed late GU toxicities of grade 2; 16.2% of patients developed grade 1 late GU toxicities; and a mere 2.3% and 9.3% of the patients showed late GI toxicities of grade 2 and grade 1, respectively.

Read more about proton therapy for prostate cancer, including interesting facts, and clarification of some common myths about proton therapy and its use in the treatment of prostate cancer:

Download the Proton Therapy Czech PDF here